Consistently, STAT3 Y640F mutations have been shown to predict response to methotrexate in a small series of patients (7), representing a putative, potential parameter to select the initial best therapy for LGLL patients. The gene discussed is STAT3; the disease is T-cell large granular lymphocyte leukemia.